United States was Harvard Bioscience’s largest region in fiscal 2025, bringing in $38.97M of $86.55M (45%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $49.91M | $48.21M | $41.74M | $38.97M | ||||||||||||
| Revenues | — | — | — | — | ||||||||||||
| Europe | $30.69M | — | — | — | ||||||||||||
| Emea | — | $33.28M | $28.41M | $26.71M | ||||||||||||
| Asia | — | — | — | — | ||||||||||||
| United Kingdom | — | — | — | — | ||||||||||||
| Greater China | $16.39M | $18.49M | — | — | ||||||||||||
| China | — | — | $13.30M | $10.97M | ||||||||||||
| Rest Of The World | $16.34M | — | — | — | ||||||||||||
| Germany | — | — | — | — | ||||||||||||
| Asia, Other | — | $8.77M | $7.10M | $6.68M | ||||||||||||
| Americas, Other | — | $3.52M | $3.60M | $3.23M | ||||||||||||
| Total | $113.34M | $112.25M | $94.14M | $86.55M |
Harvard Bioscience brought in $86.55M from its five regions in fiscal 2025, the year ended December 31, 2025. That was down 8.1% from $94.14M in fiscal 2024. United States was the largest at $38.97M (45.0%), ahead of Emea at $26.71M (30.9%) and China at $10.97M (12.7%). The other two regions brought in $9.91M combined.
Compared with fiscal 2024, every region above 2% of revenue shrank. Asia, Other held up best, down 5.9% to $6.68M, and China fell the most, down 17.5% to $10.97M.
Harvard Bioscience began breaking out Emea in fiscal 2023, Asia, Other in fiscal 2023 and Americas, Other in fiscal 2023. Harvard Bioscience stopped reporting Europe ($30.69M in fiscal 2022), Greater China ($18.49M in fiscal 2023) and Rest Of The World ($16.34M in fiscal 2022) as separate regions.
Instruments, Equipment, Software, & Accessories was Harvard Bioscience’s largest product and service line in fiscal 2025, bringing in $78.26M of $86.55M (90%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Instruments, Equipment, Software, & Accessories | $108.17M | $105.72M | $86.96M | $78.26M | |||||
| Revenues | — | — | — | — | |||||
| Service, Maintenance, & Warranty Contracts | $5.17M | $6.53M | $7.17M | $8.29M | |||||
| Total | $113.34M | $112.25M | $94.14M | $86.55M |
Harvard Bioscience brought in $86.55M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 8.1% from $94.14M in fiscal 2024. Instruments, Equipment, Software, & Accessories was the largest at $78.26M (90.4%), ahead of Service, Maintenance, & Warranty Contracts at $8.29M (9.6%).
Compared with fiscal 2024, Service, Maintenance, & Warranty Contracts grew 15.6% to $8.29M, while Instruments, Equipment, Software, & Accessories fell 10.0% to $78.26M. From fiscal 2022 to 2025, combined revenue from these lines fell from $113.34M to $86.55M, a compound annual decline of 8.6%. Instruments, Equipment, Software, & Accessories' share of the total fell from 95.4% to 90.4%.
Transferred At Point In Time was Harvard Bioscience’s largest revenue line in fiscal 2025, bringing in $82.34M of $86.55M (95%).
| Timing of Transfer of Good or Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Transferred At Point In Time | $111.93M | $108.56M | $90.42M | $82.34M |
| Transferred Over Time | $1.41M | $3.69M | $3.72M | $4.21M |
| Total | $113.34M | $112.25M | $94.14M | $86.55M |
Harvard Bioscience brought in $86.55M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 8.1% from $94.14M in fiscal 2024. Transferred At Point In Time was the largest at $82.34M (95.1%), ahead of Transferred Over Time at $4.21M (4.9%).
Compared with fiscal 2024, Transferred Over Time grew 13.4% to $4.21M, while Transferred At Point In Time fell 8.9% to $82.34M. From fiscal 2022 to 2025, combined revenue from these revenue lines fell from $113.34M to $86.55M, a compound annual decline of 8.6%. Transferred At Point In Time's share of the total fell from 98.8% to 95.1%.
Harvard Bioscience (HBIO) reports its revenue by geography, by product and service and by timing of transfer of good or service. In fiscal 2025, United States was its largest region, bringing in $38.97M (45.0% of the total), followed by Emea at $26.71M (30.9%).
United States was Harvard Bioscience's largest region in fiscal 2025, bringing in $38.97M, or 45.0% of the $86.55M total across its five regions.
Instruments, Equipment, Software, & Accessories was Harvard Bioscience's largest product and service line in fiscal 2025, bringing in $78.26M, or 90.4% of the $86.55M total across its two product and service lines.
Transferred At Point In Time was Harvard Bioscience's largest revenue line in fiscal 2025, bringing in $82.34M, or 95.1% of the $86.55M total across its two revenue lines.
Service, Maintenance, & Warranty Contracts grew faster than Instruments, Equipment, Software, & Accessories in fiscal 2025, up 15.6% from $7.17M to $8.29M. Instruments, Equipment, Software, & Accessories fell 10.0% to $78.26M.
Every figure comes from Harvard Bioscience's annual financial filings, as reported. Each line keeps the name Harvard Bioscience gives it, and years follow its fiscal calendar.
Harvard Bioscience's revenue by geography goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.